Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Announces Successful FDA Type D Meeting on Phase 3 Design for Darovasertib
Details : IDE196 (darovasertib) is a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of primary uveal melanoma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2025
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darovasertib,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Gets FDA Breakthrough Status for Darovasertib in Uveal Melanoma
Details : IDE196 (darovasertib) is a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2025
Lead Product(s) : Darovasertib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darovasertib,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : J.P. Morgan
Deal Size : $143.8 million
Deal Type : Public Offering
Details : The net proceeds will fund ongoing clinical development of IDE196 (darovasertib), a protein kinase C (PKC) inhibitor, and crizotinib, as combination therapy in metastatic uveal melanoma, including our Phase 2/3 potential registrational clinical trial.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 27, 2023
Lead Product(s) : Darovasertib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : J.P. Morgan
Deal Size : $143.8 million
Deal Type : Public Offering
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : J.P. Morgan
Deal Size : $125.0 million
Deal Type : Public Offering
IDEAYA Announces Pricing of Public Offering
Details : The net proceeds will fund ongoing clinical development of IDE196 (darovasertib), a protein kinase C (PKC) inhibitor, and crizotinib, as combination therapy in metastatic uveal melanoma, including our Phase 2/3 potential registrational clinical trial.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 24, 2023
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : J.P. Morgan
Deal Size : $125.0 million
Deal Type : Public Offering
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDE196 (darovasertib) is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. Currently being developed in combination with Crizotinib for metastatic cutaneous m...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2023
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darovasertib,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDE196 (darovasertib) is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. Currently being developed for metastatic uveal melanoma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Darovasertib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 14, 2023
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darovasertib,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2023
Lead Product(s) : Darovasertib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : Under the collaboration, Pfizer will support evaluation of IDE196 (darovasertib) and crizotinib combination therapy in the IDEAYA's planned Phase 2/3 clinical trial in Metastatic Uveal Melanoma and to continue support of the company's ongoing Phase 2 cli...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 16, 2023
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDE196 (darovasertib) is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. Currently being developed for metastatic uveal melanoma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2023
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable